Abstract
The National Lung Screening Trial (NLST) in 2011 was able to prove for the first time that screening with alow-dose CT can reduce lung carcinoma mortality by 20%. Despite the positive outcome of the NLST, there is-unlike in the USA-currently no systematic lung cancer screening in Europe. This is partly because several significantly smaller screening studies in Europe failed to show any improvement in lung cancer mortality. On the other hand, Europe's healthcare systems differ substantially from those in the United States, so that adirect transfer of US experience to Europe is not possible. For this reason, guidelines for lung cancer screening must be developed in the individual European countries to ensure that lung cancer mortality can be reduced by means of aquality-assured and cost-effective lung cancer screening. The experience and the expected results of the European screening studies can provide valuable help for these purposes.
Highlights
Daher müssen, selbst im Fall, dass kein systematisches LungenkarzinomScreening eingeführt werden sollte, Qualitätskriterien für ein individuelles Lungenkarzinom-Screening festgelegt werden
The National Lung Screening Trial (NLST) in 2011 was able to prove for the first time that screening with a low-dose CT can reduce lung carcinoma mortality by 20%
Sie können schnell und komfortabel in den für Sie relevanten Zeitschriften recherchieren und auf alle Inhalte im Volltext zugreifen
Summary
Klinik für Radiologie und Nuklearmedizin, Medizinische Universität Wien, Allgemeines Krankenhaus Wien Währingergürtel 18–20, 1090 Wien, Österreich helmut.prosch@ meduniwien.ac.at.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
